Evaluation of peritoneal membrane integrity

Journal of Nephrology

Volumn 10, Issue 5, 1997, Pages 238-244

  Krediet, Raymond T ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cancer antigen 125; Peritoneal dialysis; Solute transport; Ultrafiltration failure

Indexed keywords

ANGIOGENESIS; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIALYSATE; DIALYSIS MEMBRANE; HUMAN; MEMBRANE PERMEABILITY; MEMBRANE TRANSPORT; PERITONEAL DIALYSIS; REVIEW; SODIUM TRANSPORT; WATER TRANSPORT;

BIOLOGICAL TRANSPORT; DIALYSIS SOLUTIONS; HUMANS; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PERITONEUM;

EID: 0030718541     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Dobbie JW. Morpho-functional correlation in human mesothelium. In: La Greca, et al (eds). Peritoneal dialysis. Milano: Wichtig Editore, 1991: 33-43.
2. Dobbie JW, Zaki M, Wilson L. Ultrastructural studies on the peritoneum with special reference to chronic ambulatory peritoneal dialysis. Scott Med J 1981; 26: 213-23.
3. Di Paolo N, Sacchi G, DeMia M, et al. Morphology of the peritoneal membrane during continuous ambulatory peritoneal dialysis. Nephron 1986; 44: 204-11.
4. Gotloib L, Shostack A, Bar-Sella P, Cohen R. Continuous mesothelial injury and regeneration during long term peritoneal dialysis. Perit Dial Bull 1987; 7: 148-53.
5. Dobbie JW. Morphology of the peritoneum in CAPD. Blood Purif 1989; 7: 74-85.
6. Gotloib L, Shostack A, Wajsbrot V, Kuschmer R. The cytochemical profile of visceral mesothelium under the influence of lactated-hyperosmolar peritoneal dialysis solutions. Nephron 1995; 69: 466-71.
7. Gotloib L, Shostack A, Bar-Sella P, Eiali V. Fenestrated capillaries in human parietal and rabbit diaphragmatic peritoneum. Nephron 1985; 41: 200-2.
8. Nielsen S, Smith BL, Christensen EI, Agre P. Distribution of aquaporin CHIP in secretory and resorptive epithelia and capillary endothelia. Proc Natl Acad Sci USA 1993; 90: 7275-9.
9. Pannekeet MM, Mulder JB, Wening JJ, Struijk DG, Zweers MM, Kredier RT. Demonstration of aquaporin-CHIP in peritoneal tissue of uremic and CAPD patients. Perit Dial Int 1996; 6; Suppl 1: S54-S57.
10. Gotloib L, Bar-Sella P, Shostak A. Redupliated basal lamina of small venules and mesothelium of human parietal peritoneum. Perit Dial Bull 1985; 5: 212-5.
11. Di Paolo N, Sacchi G. Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): an in vivo model for the study of diabetic microangiopathy. Perit Dial Int 1989; 9: 41-5.
12. Dobbie JW, Lloyd JK, Gall CA. Categorization of ultrastructural changes in peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients. Adv Perit Dial 1990; 6: 3-12.
13. Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992; 12: 14-27.
14. Dobbie JW, Anderson JD, Hind C. Long-term effects of peritoneal dialysis on peritoneal morphology. Perit Dial Int 1994; 14; suppl 3: S16-S20.
15. Honda K, Nitta K, Yamara S, Nikei W. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron 1996; 72: 171-6.
16. Nagel W, Kuchinsky W. Study of the permeability of the isolated dog mesentery. Eur J Clin Invest 1970; 1: 149-54.
17. Rasio EA. Metabolic control of permeability of the isolated dog mesentery. Am J Physiol 1994; 267: F861-F870.
18. Flessner MF. Osmotic barrier of the parietal peritoneum. Am J Physiol 1994; 267: F861-F870.
19. Grotte G. Passage of dextran molecules across the blood-lymph barrier. Acta Chir Scand 1956; 211 (suppl): 1-84.
20. Zemel D, Krediet RT, Koomen GCM, Struijk DG, Arisz L. Day to day variability of protein transport used as a method for analyzing peritoneal permeability in CAPD. Perit Dial Int 1991; 11: 217-23.
21. Krediet RT, Zemel D, Struijk DG, Koomen GCM, Arisz L. Individual characterization of the peritoneal restriction barrier to macromolecules. Adv Perit Dial 1991; 7: 15-20.
22. Imholz ALT, Koomen GCM, Struijk DG, Arisz L, Krediet RT. Effect of dialysate osmolarity on the transport of low-molecular weight solutes and proteins during CAPD. Kidney Int 1993; 43: 1339-46.
23. Krediet RT, Boeschoten EW, Zuyderhoudt FMJ, Arisz L. The relationship between peritoneal glucose absorption and body fluid loss by ultrafiltration during continuous ambulatory peritoneal dialysis. Clin Nephrol 1987; 17: 43-52.
24. Rippe B, Stelin G, Haraldson B. Computer simulations of peritoneal fluid transport in CAPD. Kidney Int 1991; 40: 315-25.
25. Nolph KD, Twardowski ZJ, Popovich RP, Rubin J. Equilibration of peritoneal dialysis solutions during long-dwell exchanges. J Lab Clin Med 1979; 93: 246-56.
26. Canaud B, Liendo-Liendo C, Claret G, Mion H, Mion C. Etude "in situ" de la cinétique du l'ultrafiltration en cours de dialyse péritonéale avec périodes de diffusion prolongé. Néphrologie 1980; 1: 126-32.
27. Heimburger O, Waniewski J, Werynski A, Tranaeus A, Lindholm B. Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 1990; 38: 495-506.
28. Chen TW, Khanna R, Moore H, Twardowski ZJ, Nolph KD. Sieving and reflection coefficients for sodium salts and glucose during peritoneal dialysis. J Am Soc Nephrol 1991; 2: 1092-1100.
29. Heimburger O, Waniewski J, Werynski A, Lindholm B. A quantitative description of solute and fluid transport during peritoneal dialysis. Kidney Int 1992; 41: 1320-32.
30. Waniewski J, Heimburger O, Werynski A, Lindholm B. Aqueous solute concentration and evaluation of mass transport coefficients in peritoneal dialysis. Nephrol Dial Transplant 1992; 7: 50-6.
31. Ho-dac-Pannekeet MM, Krediet RT. Water channels in the peritoneum. Perit Dial Int 1996; 16: 255-9.
32. Ho-dac-Pannekeet MM, Schonten N, Langedijk MJ, et al. Peritoneal transport characteristics with glucose polymer based dialysate. Kidney Int 1996; 50: 979-86.
33. Rippe B, Stelin G. Simulations of peritoneal solute transport during CAPD. Application of two-pore formalism. Kidney Int 1989; 35: 1234-44.
34. Zemel D, Krediet RT. Cytokine patterns in the effluent of continuous ambulatory peritoneal dialysis: relationship to peritoneal permeability. Blood Purif 1996; 14: 198-216.
35. Ho-dac-Pannekeet MM, Krediet RT. Inflammatory changes in vivo during CAPD: what can the effluent tell us? Kidney Int 1996; 50; suppl 56: S12-S16.
36. Grahame GR, Torchia MG, Dankewich KA, Ferguson IA. Surface active material in peritoneal effluent of CAPD patients. Perit Dial Bull 1985; 5: 109-11.
37. Di Paolo N, Buoncristiani U, Capotondo L, et al. Phosphotidylcholine and peritoneal transport during peritoneal dialysis. Nephron 1986; 44: 365-70.
38. Williams JD, Beavis JM. Phosphatidylcholine and peritoneal dialysis. Contr Nephrol 1990; 85: 142-9.
39. Beavis J, Harwood JL, Coles GA, Williams JD. Synthesis of phospholipids by human peritoneal mesothelial cells. Perit Dial Int 1994; 14: 348-55.
40. Strapans I, Piel CF, Felts JM. Analysis of selected plasma constituents in continuous ambulatory peritoneal dialysis effluent. Am J Kidney Dis 1986; 7: 490-4.
41. Davies M, Stylianou E, Yung S, Thomas GJ, Coles GA, Williams JD. Proteoglycans of CAPD dialysate fluid and mesothelium. Contr Nephrol 1990; 85: 131-41.
42. Yung S, Coles GA, Williams JD, Davies M. The source and possible significance of hyaluronan in the peritoneal cavity. Kidney Int 1994; 46: 527-33.
43. Roboz J, Greaves J, Silides D. Chahinian AP, Holland JF. Hyaluronic acid content of effusion as a diagnostic aid for malignant mesothelioma. Cancer Res 1985; 45: 1850-4.
44. Yung S, Thomas GJ, Stylianou E, Williams JD, Coles GA, Davies M. Source of peritoneal proteoglycans. Human peritoneal mesothelial cells synthesize and secrete mainly small dermatan sulfate proteoglycans. Am J Pathol 1995; 146: 520-9.
45. Bast RC jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelian ovarian cancer. New Engl J Med 1983; 309: 883-7.
46. Klug TL, Bast RC jr, Niloff JM, Knapp RC, Zurawski VR. Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA125) associated with human epighelial ovarian carcinomas. Cancer Res 1984; 44: 1048-53.
47. Kabawat SE, Bast RC, Bhan AK, Welch WR, Knapp RC, Colvin RB. Tissue distribution of a coelomic-epithelial-related antigen recognized by the monoclonal antibody OC 125. Int J Gynecol Pathol 1983; 2: 275-85.
48. Pannekeet MM, Zemel D, Koomen GCM, Struijk DG, Krediet RT. Dialysate markers of peritoneal tissue during peritonitis and in stable CAPD. Perit Dial Int 1995; 15: 217-25.
49. Koomen GCM, Betjes MGH, Zemel D, Krediet RT, Hoek FJ. Cancer antigen 125 is locally produced in the peritoneal cavity during continuous ambulatory peritoneal dialysis. Perit Dial Int 1994; 14: 132-6.
50. Visser CE, Brouwer-Steenbergen JJE, Betjes MGH, Koomen GCM, Beelen RHJ, Krediet RT. Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients. Neph Dial Transplant 1995; 10: 64-9.
51. Pannekeet MM, Koomen GCM, Struijk DG, Krediet RT. Dialysate CA 125 in stable CAPD patients: no relation with transport parameters. Clin Nephrol 1995; 44: 248-54.
52. Jörres A, Ludat K, Topley N, et al. Human peritoneal fibroblasts synthesize the chemotactic peptide interleukin-8 (Abstract). Neph Dial Transplant 1994; 9: 1022.
53. Ludat K, Topley N, Lang J, Gahl GM, Frei U, Jōrres A. The production of pro-inflammatory cytokines (IL-6, IL-8) in human peritoneal fibroblasts is upregulated following stimulation with IL-1β and/or TNFα (Abstract). J Am Soc Nephrol 1994; 5: 463.
54. Nagata Y, Matsumura F, Motoyoski H, Yamasaky H, Fukuda K, Tanaka S. Secretion of hyaluronic acid from sybovial fibroblasts is enhanced by histamine: a newly observed metabolic effect of histamine. J Lab Clin Med 1992; 120: 707-12.
55. Laurant TC, Frase JRE. The properties and turnover of hyaluronan. In: Evered D, Whelan J, eds. Functions of proteoglycans. Ciba Foundation Symposium, vol 124. Chichester: Wiley, 1986; 9-29.
56. Fessler JH, Fessler LI. Biosynthesis of procollagen. Ann Rev Biochem 1978; 47: 129-62.
57. Rohde H, Vargas L, Hahn E, Kalbfleisch H, Bruguera M, Timpl R. Radioimmunoassay for type III procollagen peptide and its application to human liver disease. Eur J Clin Invest 1979; 9: 451-9.
58. Shahin M, Schuppan D, Waldherr R, et al. Serum procollagen peptides and collagen type VI for the assessment of activity and degree of hepatic fibrosis in schistosomiasis and alcoholic liver disease. Hepatology 1992; 15: 637-44.
59. Parfitt AM, Simon LS, Villanueva AR, Krane SM. Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with iliac bone formation rate and comparison with total alkaline phosphatase. J Bone Miner Res 1987; 2: 427-36.
60. Joffe P, Jensen LT. Type I and III procollagens in CAPD: markers of peritoneal fibrosis. Adv Perit Dial 1991; 7: 158-60.
61. Digenis GE, Dombros NV, Christophoraki M, et al. Procollagen type-I in serum and dialysate of continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1993; 13; (suppl) 2:S480-S483.
62. Heimburger O, Waniewski J, Werynski A, Tranaeus A, Lindholm B. Peritoneal transport in CAPD patiens with permanent loss of ultrafiltration capacity. Kidney Int 1990; 38: 495-506.
63. Struijk DG, Krediet RT, Koomen GCM, et al. Functional characteristics of the peritoneal membrane in long-term continuous ambulatory peritoneal dialysis. Nephron 1991; 59: 213-20.
64. Selgas R, Fernandez-Reyes M-J, Bosque E, et al. Functional longevity of the human peritoneum: how long is continuous peritoneal dialysis possible? Results of a prospective median long-term study. Am J Kidney Dis 1994; 23: 64-73.
65. Davies SJ, Bryan J, Philips L, Russel GI. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Neph Dial Transplant 1996; 11: 448-506.
66. Twardowski ZJ, Nolph KD, Khanna R, et al. Peritoneal equilibration test. Perit Dial Bull 1987; 7: 138-47.
67. Davies SJ, Brown B, Bryan J, Russel GI. Clinical evaluation of the peritoneal equilibration test: a population based study. Neph Dial Transplant 1993; 8: 64-70.
68. Krediet RT, Boeschoten EW, Zuyderhoudt FMJ, Arisz L. Peritoneal transport characteristics of water, low molecular weight solutes and proteins during long-term continuous ambulatory peritoneal dialysis. Perit Dial Bull 1986; 6: 61-5.
69. Ho-dac-Pannekeet MM, Atasever B, Struijk DG, Krediet RT. Analysis of ultrafiltration failure in peritoneal dialysis patients by means of standard peritoneal permeability analysis. Perit Dial Int 1997; 17: 144-50.
70. Kush RD, Hallet MD, Ota K, et al. Long-term continuous ambulatory peritoneal dialysis: mass transfer and nutritional and metabolic stability. Blood Purif 1990; 8: 1-13.
71. Lameire NH, Vanholder R, Veys D, Lambert MC, Ringoir S. A longitudinal five year survey of urea kinetic parameters in CAPD patients. Kidney Int 1992; 42: 426-32.
72. Krediet RT, Zemel D, Imholz ALT, Struijk DG. Impact of surface area and permeability on solute clearances. Perit Dial Int 1994; 14; (suppl) 3: S70-S77.
73. Monquil MCJ, Imholz ALT, Struijk DG, Krediet RT. Does impaired transcellular water transport contribute to net ultrafiltration failure during CAPD? Perit Dial Int 1995; 15: 42-8.
74. Pannekeet MM, Imholz ALT, Struijk DG, et al. The standard peritoneal permeability analysis: a tool for the assessment of peritoneal permeability characteristics in CAPD patients. Kidney Int 1995; 48: 866-75.
75. Slingeneyer A, Mion C, Mourad G, Canaud B, Faller B, Béraud JJ. Progressive sclerosing peritonitis: a late and severe complication of maintenance peritoneal dialysis. Trans Am Soc Artif Intern Organs 1983; 29: 633-40.
76. Verger C, Celicout B. Peritoneal permeability and encapsulating peritonitis. Lancet 1985; 1: 986-7.
77. Krediet RT, Struijk DG, Boeschoten EW, et al. The time course of peritoneal transport kinetics in continuous ambulatory peritoneal dialysis patients who develop sclerosing peritonitis. Am J Kidney Dis 1989; 13: 299-307.
78. Hendriks PMEM, Ho-dac-Pannekeet MM, Van Gulik ThM, et al. Peritoneal sclerosis in chronic peritoneal dialysis patients. Analysis of clinical presentation, risk factors and peritoneal transport kinetics. Perit Dial Int 1997; 17: 136-43.
79. Dobbie JW, Krediet RT, Twardowski ZJ, Nichols WK. A 39-year old man with loss of ultrafiltration. Perit Dial Int 1994; 14: 384-94.
80. Struijk DG, Krediet RT, Koomen GCM, Boeschoten EW, Hoek FJ, Arisz L. A prospective study of peritoneal transport in CAPD patients. Kidney Int 1994; 45: 1739-44.
81. Park MS, Lee SH, Chung SH, Lee EY, et al. Stability of peritoneal solute and water transport with time on CAPD (Abstract). Blood Purif 1996; 14: abstract book 019.
82. Ho-dac-Pannekeet MM, Koopmans JG, Struijk DG, Krediet RT. Restriction coefficients of low molecular weight solutes and macromolecules during peritoneal dialysis. Adv Perit Dial 1997; 13: 72-6.
83. Ziegler C, Torchia M, Grahame GR, Ferguson IA. Peritoneal surface-active material in continuous ambulatory peritoneal dialysis (CAPD) patients. Perit Dial Int 1989; 9: 47-9.
84. Krack G, Viglino G, Cavelli PL, et al. Intraperitoneal administration of phosphatidylcholine improves ultrafiltration in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1992; 12: 359-64.
85. Beavis J, Harwood JL, Coles GA, Williams JD. Intraperitoneal phosphatidylcholine levels in patients on continuous ambulatory peritoneal dialysis do not correlate with adquacy of ultrafiltration. J Am Soc Nephrol 1993; 3: 1954-60.
86. Ho-dac-Pannekeet MM, Hiralall JK, Struijk DG, Krediet RT. Markers of peritoneal mesothelial cells during treatment with peritoneal dialysis. Adv Perit Dial 1997; 13: 17-22.
87. Ho-dac-Pannekeet MM, Hiralall JK, Struijk DG, Krediet RT. Longitudinal follow-up of CA 125 in peritoneal effluent. Kidney Int 1997; 51: 888-93.
88. Krediet RT, Pannekeet MM, Stegeman G, Struijk DG. Markers of peritoneal tissue in stable CAPD patients and patients with sclerosing peritonitis (Abstract). Perit Dial Int 1995; 15; (suppl) 2: S43.
89. Krediet RT, Boeschoten EW, Zuyderhoudt FMJ, Strackee J, Arisz L. Simple assessment of the efficacy of peritoneal transport in continuous ambulatory peritoneal dialysis patients. Blood Purif 1986; 4: 194-203.